Thomas B. Smith - 27 Jan 2022 Form 4 Insider Report for BIODELIVERY SCIENCES INTERNATIONAL INC

Role: Chief Medical Officer
Signature: /s/ Thomas Smith, MD.
Issuer symbol: N/A
Transactions as of: 27 Jan 2022
Net transactions value: +$948,621
Form type: 4
Filing time: 31 Jan 2022, 16:58:33 UTC
Next filing: 22 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDSI	Common Stock	Options Exercise	$0	+17,361	+87%	$0.000000	37,315	27 Jan 2022	Direct
transaction	BDSI	Common Stock	Options Exercise	$0	+7,548	+20%	$0.000000	44,863	31 Jan 2022	Direct
transaction	BDSI	Common Stock	Options Exercise	$0	+7,667	+17%	$0.000000	52,530	31 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BDSI	Stock Options (right to buy)	Award	$948,621	+259,186		$3.66	259,186	27 Jan 2022	Common Stock	259,186	$3.66	Direct	F1, F2
transaction	BDSI	Restricted Stock Units	Award	$0	+46,448		$0.000000	46,448	27 Jan 2022	Common Stock	46,448	$0.000000	Direct	F3, F4
transaction	BDSI	Restricted Stock Units	Options Exercise	$0	-17,361	-33%	$0.000000	34,722	27 Jan 2022	Common Stock	17,361	$0.000000	Direct	F5
transaction	BDSI	Restricted Stock Units	Options Exercise	$0	-7,548	-50%	$0.000000	7,549	29 Jan 2022	Common Stock	7,548	$0.000000	Direct	F6
transaction	BDSI	Restricted Stock Units	Options Exercise	$0	-7,667	-100%	$0.000000^*	0	31 Jan 2022	Common Stock	7,667	$0.000000	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
F2	The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F3	The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F4	Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
F5	The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
F6	The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Plan. The remaining RSUs vest on January 29, 2023.
F7	The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended.